Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10035574 | 0.85 | MEN1 (0.58) | MEN1KMT2AHTR7SMN1; SMN2ALDH1A1 | |
| SCHEMBL8981937 | 0.83 | MEN1 (0.57) | ABCB1MEN1KMT2AHTR7SMN1; SMN2 | |
| SCHEMBL10035586 | 0.80 | ABCB1 (0.54) | ABCB1TMEM97SIGMAR1HTR7 | |
| SCHEMBL10035619 | 0.80 | ABCB1 (0.54) | ABCB1TMEM97SIGMAR1HTR7 | |
| SCHEMBL10035605 | 0.80 | ABCB1 (0.56) | ABCB1TMEM97SIGMAR1HTR7 | |
| Hydrochloric Acid SCHEMBL2139849 | 0.80 | ABCB1 (0.53) | ABCB1TMEM97SIGMAR1HTR7 | |
| Hydrochloric Acid SCHEMBL2138435 | 0.80 | ABCB1 (0.53) | ABCB1TMEM97SIGMAR1 | |
| Hydrochloric Acid SCHEMBL5395710 | 0.79 | ABCB1 (0.55) | ABCB1TMEM97SIGMAR1 | |
| SCHEMBL2139371 | 0.79 | CCR1 (0.53) | ABCB1TMEM97SIGMAR1HTR7 | |
| SCHEMBL10035589 | 0.79 | ABCB1 (0.52) | ABCB1TMEM97SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088450-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | ABCB1 551/4885MEN1 1093/4885KMT2A 2533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.